Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Name: Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
License: Public Domain

National Cancer Institute (NCI) · clinicaltrials

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

metastatic nasopharyngeal carcinoma, metastatic nasopharyngeal keratinizing squamous cell carcinoma, metastatic nasopharyngeal nonkeratinizing carcinoma, metastatic nasopharyngeal undifferentiated carcinoma, nasopharyngeal nonkeratinizing carcinoma, recurrent nasopharyngeal carcinoma

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Record · ID 28329 · SHA-256 17c3746fc8cd5ac2
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.